StrongHolt Therapeutics is a biotechnology company dedicated to developing best-in-class gene therapies for Duchenne muscular dystrophy (DMD). Our innovative approach addresses the key limitations of current treatments, offering a safe, curative, single-dose solution. With proven preclinical success, we are poised to transform the lives of patients with DMD.